Labcorp Holdings Inc. vs Quest Diagnostics Incorporated: Strategic Comparison

This in-depth comparison examines Labcorp Holdings Inc. and Quest Diagnostics Incorporated across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Labcorp Holdings Inc. on its own, evaluating Quest Diagnostics Incorporated, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Labcorp Holdings Inc. and Quest Diagnostics Incorporated is widest.

On the headline numbers, Labcorp Holdings Inc. reports annual revenue of $14.0B against $11.0B for Quest Diagnostics Incorporated, while their respective market capitalizations stand at $25.1B and $27.2B. Labcorp Holdings Inc. is headquartered in United States and Quest Diagnostics Incorporated operates from United States, and those different home markets shape how each company competes.

Labcorp Holdings Inc.: Labcorp is one of the two largest independent clinical laboratory operators in the US, alongside Quest Diagnostics. Headquartered in Burlington, North Carolina, it has about 71,000 employees, serves clients in roughly 100 countries, and performed more than 750 million tests in 2025. Since spinning off its clinical development CRO business as Fortrea in 2023, the company reports two segments: Diagnostics Laboratories and Biopharma Laboratory Services.

Quest Diagnostics Incorporated: Quest Diagnostics is a Secaucus, New Jersey-based provider of diagnostic information services. It does not make drugs or run hospitals. It runs the labs that process blood, urine and tissue samples ordered by doctors, hospitals, employers and consumers, then sends results back through EHRs and the MyQuest app. Quest says it serves about one in three adult Americans and half the physicians and hospitals in the U.S. each year. Since 2024 it has also run LifeLabs in Canada.

Labcorp Holdings Inc. and Quest Diagnostics Incorporated pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Labcorp Holdings Inc. and Quest Diagnostics Incorporated.

Labcorp Holdings Inc. business model: Labcorp makes money in two segments. Diagnostics Laboratories ($10.88 billion of 2025 revenue, about 78%) collects specimens through roughly 2,000 patient service centers, in-office phlebotomists, and courier and aircraft routes, runs routine and specialty tests in automated labs, and bills commercial insurers, Medicare and Medicaid, physicians, hospitals, and consumers. Biopharma Laboratory Services ($3.10 billion, about 22%) earns contract fees from drug, biotech, and device companies for central-laboratory testing in clinical trials and early-development (preclinical) studies; it ended 2025 with an $8.72 billion backlog. Hospital lab management and outreach acquisitions feed additional volume into the diagnostics network.

Quest Diagnostics Incorporated business model: Quest Diagnostics earns fee-for-service revenue for lab tests ordered by physicians, hospitals, health plans, employers and consumers. Diagnostic Information Services (DIS) produced $2.978B of the company's $3.043B Q2 2026 revenue. Payment comes from commercial insurers, Medicare and Medicaid, hospitals that send it outreach or reference work, employers, and patients paying directly through questhealth.com. Volume drives the economics. Specimens collected at about 2,200 patient service centers and physician offices are moved by courier, and on some routes by air, to regional labs. High-throughput automated testing there keeps the cost per test low. Routine tests such as metabolic panels, lipid panels and blood counts make up most of the volume. Advanced diagnostics like AD-Detect Alzheimer's blood tests, Haystack MRD, genetics and cardiometabolic panels carry higher prices. Hospital outreach acquisitions and Co-Lab lab-management deals add volume.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Labcorp Holdings Inc. stack up against those of Quest Diagnostics Incorporated.

Labcorp Holdings Inc. competitive advantage: Labcorp's edge is physical density plus breadth. About 2,000 patient service centers, more than 6,000 in-office phlebotomists, a nightly aircraft fleet out of Burlington, and large automated hub labs keep cost per test low. On top of that sits a specialty menu (oncology, women's health, genetics, neurology) and a central-lab business that supported more than 85% of new drugs and therapeutic products the FDA approved in 2025. A new entrant would need both the collection footprint and payer contracts to compete.

Quest Diagnostics Incorporated competitive advantage: Quest's main advantage is density. It has a national patient service center footprint, in-network contracts with most major U.S. health plans, EHR connections to physician offices, and regional labs that spread fixed costs across hundreds of millions of tests a year. Only Labcorp operates at comparable U.S. scale. That scale lets Quest offer health systems a lower-cost option for outreach testing. Deals with NewYork-Presbyterian, Corewell Health and Fresenius Medical Care show how it turns that into new volume.

Future prospects matter as much as current results. The growth strategies below explain how Labcorp Holdings Inc. and Quest Diagnostics Incorporated each plan to expand from here.

Labcorp Holdings Inc. growth strategy: Labcorp's stated priorities are leading in specialty testing, being the partner of choice for health systems and regional labs, growing consumer health, and using technology and AI to cut cost. In 2025 it launched more than 130 new tests and signed or closed 13 health-system and regional lab transactions; 2026 deals include outreach assets from Crouse Health, Parkview Health, and Tribal Diagnostics. The MyLabcorp app and Labcorp OnDemand push direct-to-consumer testing.

Quest Diagnostics Incorporated growth strategy: Quest is growing in four ways. First, it buys hospital outreach labs and signs Co-Lab Solutions lab-management deals, such as its Corewell Health joint venture in Michigan. Second, it adds large partner volume, such as dialysis testing for Fresenius Medical Care. Third, it pushes higher-value advanced diagnostics, including AD-Detect Alzheimer's blood tests, Haystack MRD (approved by New York State in 2026) and liver fibrosis testing. Fourth, it sells consumer-initiated tests through questhealth.com and wearable and wellness partners. Automation and AI in specimen processing, cervical cancer screening and the IntelliDraw collection tool are meant to offset reimbursement pressure.

A closer look at the financial trajectory of Labcorp Holdings Inc. and Quest Diagnostics Incorporated rounds out the comparison.

Labcorp Holdings Inc.: Revenue rose from $13.01 billion in 2024 to $13.95 billion in 2025 (up 7.2%), with diluted EPS of $10.46, adjusted EPS of $16.44, and free cash flow of $1.21 billion. Momentum carried into 2026: second-quarter revenue reached $3.73 billion (up 5.8%, 4.2% organic), adjusted operating margin widened 70 basis points to 15.8%, and adjusted EPS climbed 14.9% to $4.99. In July 2026 management raised full-year guidance to 5.4%-6.3% revenue growth and adjusted EPS of $18.10-$18.55, and the board added $1.0 billion to the buyback authorization.

Quest Diagnostics Incorporated: Quest's results follow three phases. Before the pandemic, revenue grew slowly, from $7.21B in 2016 to $7.73B in 2019. COVID-19 testing then lifted revenue to $10.79B and net income to $1.995B in 2021. Revenue fell back to $9.25B in 2023 as that demand faded. Acquisitions and organic volume restarted growth: revenue reached $9.87B in 2024 and $11.035B in 2025, when operating income was $1.556B and operating cash flow was $1.886B. In the first half of 2026, revenue rose 9.7% to $5.938B and net income attributable to Quest rose 13.9% to $572M. Quest raised its quarterly dividend 7.5% to $0.86 per share in 2026.